Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

Abstract Atherosclerotic cardiovascular diseases are the leading cause of adverse outcomes in patients with type 2 diabetes, and all new anti-diabetic agents are mandated to undergo cardiovascular outcome trials (CVOTs). Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are incretin mimetics that...

Full description

Bibliographic Details
Main Authors: Miguel Melo, Cristina Gavina, José Silva-Nunes, Luís Andrade, Davide Carvalho
Format: Article
Language:English
Published: BMC 2021-07-01
Series:Diabetology & Metabolic Syndrome
Subjects:
Antidiabetic drug
GLP-1 RA
Cardiovascular disease
Cardiovascular outcome trials
Type 2 diabetes
Online Access:https://doi.org/10.1186/s13098-021-00698-5

Internet

https://doi.org/10.1186/s13098-021-00698-5

Similar Items